AEVA is a biotech company, aiming at addressing unmet medical needs, with multimodal molecular diagnostic approaches. The acronym of the name stands for Advanced Extracellular Vesicle Applications, pointing out the idea of exploiting extracellular vesicles to identify innovative clinical applications and to advance liquid biopsy testing.

A group of researchers from CIBIO (Department of Cellular, Computational and Integrative Biology of the University of Trento) founded the company in December 2019. The researchers are all inventors of the patent protecting AEVA core technology.